A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS

Oropharyngeal candidiasis is the most common opportunistic infection among persons infected with human immunodeficiency virus (HIV). Use of some agents is hampered by lack of efficacy, emergence of resistance, adverse events, and need for intravenous administration. Posaconazole is an extended-spect...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical infectious diseases Vol. 42; no. 8; p. 1179
Main Authors:	Vazquez, Jose A, Skiest, Daniel J, Nieto, Leopoldo, Northland, Rebeca, Sanne, Ian, Gogate, Jagadish, Greaves, Wayne, Isaacs, Randi
Format:	Journal Article
Language:	English
Published:	United States 15.04.2006
Subjects:	Adult Aged AIDS-Related Opportunistic Infections - drug therapy Antifungal Agents - therapeutic use Candida - classification Candida - isolation & purification Candidiasis - drug therapy Candidiasis, Oral - drug therapy Double-Blind Method Ethnic Groups Female Fluconazole - therapeutic use Humans Male Microbial Sensitivity Tests Middle Aged Pharyngeal Diseases - drug therapy Pharyngeal Diseases - microbiology Probability Treatment Outcome Triazoles - pharmacology Triazoles - therapeutic use
ISSN:	1537-6591, 1537-6591
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Oropharyngeal candidiasis is the most common opportunistic infection among persons infected with human immunodeficiency virus (HIV). Use of some agents is hampered by lack of efficacy, emergence of resistance, adverse events, and need for intravenous administration. Posaconazole is an extended-spectrum triazole with potent in vitro activity against Candida species, including Candida albicans, Candida glabrata, and Candida krusei (including fluconazole-resistant strains). This multicenter, randomized, evaluator-blinded study of subjects with HIV infection and oropharyngeal candidiasis compared efficacy of posaconazole with that of fluconazole. Subjects received either 200 mg of posaconazole or fluconazole oral suspension on day 1, followed by 100 mg/day for 13 days. The primary study end point--clinical success (cure or improvement) on day 14--was evaluated for 329 subjects. Durability of clinical success was evaluated on day 42. Three hundred fifty subjects received posaconazole (n = 178) or fluconazole (n = 172). Clinical success occurred in 155 (91.7%) of 169 posaconazole recipients and in 148 (92.5%) of 160 fluconazole recipients (95% confidence interval, -6.61% to 5.04%), indicating that posaconazole was not inferior to fluconazole. On day 14, mycological success was 68% in both arms, but by day 42, significantly more posaconazole recipients than fluconazole recipients continued to have mycological success (40.6% vs. 26.4%; P=.038). Fewer posaconazole recipients than fluconazole recipients experienced clinical relapse (31.5% vs. 38.2%). Adverse events were similar between treatment arms. Results demonstrate that posaconazole was as effective as fluconazole in producing a successful clinical outcome. However, posaconazole was more effective in sustaining clinical success after treatment was stopped.
AbstractList	Oropharyngeal candidiasis is the most common opportunistic infection among persons infected with human immunodeficiency virus (HIV). Use of some agents is hampered by lack of efficacy, emergence of resistance, adverse events, and need for intravenous administration. Posaconazole is an extended-spectrum triazole with potent in vitro activity against Candida species, including Candida albicans, Candida glabrata, and Candida krusei (including fluconazole-resistant strains).BACKGROUNDOropharyngeal candidiasis is the most common opportunistic infection among persons infected with human immunodeficiency virus (HIV). Use of some agents is hampered by lack of efficacy, emergence of resistance, adverse events, and need for intravenous administration. Posaconazole is an extended-spectrum triazole with potent in vitro activity against Candida species, including Candida albicans, Candida glabrata, and Candida krusei (including fluconazole-resistant strains).This multicenter, randomized, evaluator-blinded study of subjects with HIV infection and oropharyngeal candidiasis compared efficacy of posaconazole with that of fluconazole. Subjects received either 200 mg of posaconazole or fluconazole oral suspension on day 1, followed by 100 mg/day for 13 days. The primary study end point--clinical success (cure or improvement) on day 14--was evaluated for 329 subjects. Durability of clinical success was evaluated on day 42.METHODSThis multicenter, randomized, evaluator-blinded study of subjects with HIV infection and oropharyngeal candidiasis compared efficacy of posaconazole with that of fluconazole. Subjects received either 200 mg of posaconazole or fluconazole oral suspension on day 1, followed by 100 mg/day for 13 days. The primary study end point--clinical success (cure or improvement) on day 14--was evaluated for 329 subjects. Durability of clinical success was evaluated on day 42.Three hundred fifty subjects received posaconazole (n = 178) or fluconazole (n = 172). Clinical success occurred in 155 (91.7%) of 169 posaconazole recipients and in 148 (92.5%) of 160 fluconazole recipients (95% confidence interval, -6.61% to 5.04%), indicating that posaconazole was not inferior to fluconazole. On day 14, mycological success was 68% in both arms, but by day 42, significantly more posaconazole recipients than fluconazole recipients continued to have mycological success (40.6% vs. 26.4%; P=.038). Fewer posaconazole recipients than fluconazole recipients experienced clinical relapse (31.5% vs. 38.2%). Adverse events were similar between treatment arms.RESULTSThree hundred fifty subjects received posaconazole (n = 178) or fluconazole (n = 172). Clinical success occurred in 155 (91.7%) of 169 posaconazole recipients and in 148 (92.5%) of 160 fluconazole recipients (95% confidence interval, -6.61% to 5.04%), indicating that posaconazole was not inferior to fluconazole. On day 14, mycological success was 68% in both arms, but by day 42, significantly more posaconazole recipients than fluconazole recipients continued to have mycological success (40.6% vs. 26.4%; P=.038). Fewer posaconazole recipients than fluconazole recipients experienced clinical relapse (31.5% vs. 38.2%). Adverse events were similar between treatment arms.Results demonstrate that posaconazole was as effective as fluconazole in producing a successful clinical outcome. However, posaconazole was more effective in sustaining clinical success after treatment was stopped.CONCLUSIONSResults demonstrate that posaconazole was as effective as fluconazole in producing a successful clinical outcome. However, posaconazole was more effective in sustaining clinical success after treatment was stopped. Oropharyngeal candidiasis is the most common opportunistic infection among persons infected with human immunodeficiency virus (HIV). Use of some agents is hampered by lack of efficacy, emergence of resistance, adverse events, and need for intravenous administration. Posaconazole is an extended-spectrum triazole with potent in vitro activity against Candida species, including Candida albicans, Candida glabrata, and Candida krusei (including fluconazole-resistant strains). This multicenter, randomized, evaluator-blinded study of subjects with HIV infection and oropharyngeal candidiasis compared efficacy of posaconazole with that of fluconazole. Subjects received either 200 mg of posaconazole or fluconazole oral suspension on day 1, followed by 100 mg/day for 13 days. The primary study end point--clinical success (cure or improvement) on day 14--was evaluated for 329 subjects. Durability of clinical success was evaluated on day 42. Three hundred fifty subjects received posaconazole (n = 178) or fluconazole (n = 172). Clinical success occurred in 155 (91.7%) of 169 posaconazole recipients and in 148 (92.5%) of 160 fluconazole recipients (95% confidence interval, -6.61% to 5.04%), indicating that posaconazole was not inferior to fluconazole. On day 14, mycological success was 68% in both arms, but by day 42, significantly more posaconazole recipients than fluconazole recipients continued to have mycological success (40.6% vs. 26.4%; P=.038). Fewer posaconazole recipients than fluconazole recipients experienced clinical relapse (31.5% vs. 38.2%). Adverse events were similar between treatment arms. Results demonstrate that posaconazole was as effective as fluconazole in producing a successful clinical outcome. However, posaconazole was more effective in sustaining clinical success after treatment was stopped.
Author	Northland, Rebeca Isaacs, Randi Greaves, Wayne Sanne, Ian Nieto, Leopoldo Vazquez, Jose A Gogate, Jagadish Skiest, Daniel J
Author_xml	– sequence: 1 givenname: Jose A surname: Vazquez fullname: Vazquez, Jose A email: jvazque1@hfhs.org organization: Division of Infectious Diseases, Henry Ford Hospital and Wayne State University, Detroit, Michigan 48201, USA. jvazque1@hfhs.org – sequence: 2 givenname: Daniel J surname: Skiest fullname: Skiest, Daniel J – sequence: 3 givenname: Leopoldo surname: Nieto fullname: Nieto, Leopoldo – sequence: 4 givenname: Rebeca surname: Northland fullname: Northland, Rebeca – sequence: 5 givenname: Ian surname: Sanne fullname: Sanne, Ian – sequence: 6 givenname: Jagadish surname: Gogate fullname: Gogate, Jagadish – sequence: 7 givenname: Wayne surname: Greaves fullname: Greaves, Wayne – sequence: 8 givenname: Randi surname: Isaacs fullname: Isaacs, Randi
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/16575739$$D View this record in MEDLINE/PubMed
BookMark	eNpNkMtOwzAQRS1URB_AJyCv2IXGie0ky6o8WgmJBY9t5MTj1lViB9spop_BFxOJgljNaHTukeZO0chYAwhdkviGxDmfs5hQlp2gCWFpFnFWkNG_fYym3u_imJA8ZmdoTDjLWJYWE_S1wG3fBF2DCeCwE0baVh9A4uC0aDDsRdOLoM0Gd9aL2hpxsA3gPTjfe6ya_u-krMNhC0MQRGgHH7YKW2e7rXCfZgODrR70WmrhtcfaYN9XO6iDxx86bPFq_TZfrG-fz9GpEo2Hi-Ocodf7u5flKnp8elgvF49RTVkSIkEJCJ4qyXnNCimrQtE4FVxUiaSKCMlzUhQqrTLOC4grDlWeSppTBbIgRCYzdP3j7Zx978GHstW-hqYRBmzvS57lhHOaDODVEeyrFmTZOd0OL5W_LSbf2Ed4Rg
CitedBy_id	crossref_primary_10_1016_j_cden_2007_10_006 crossref_primary_10_1586_14787210_7_2_165 crossref_primary_10_1007_s15010_013_0504_1 crossref_primary_10_1016_j_jchromb_2009_06_022 crossref_primary_10_1086_523576 crossref_primary_10_4065_83_9_1046 crossref_primary_10_4137_CMT_S1948 crossref_primary_10_1016_j_archger_2016_04_001 crossref_primary_10_1002_jhm_412 crossref_primary_10_3390_pharmacy3040210 crossref_primary_10_1517_14656560902952854 crossref_primary_10_1111_j_1439_0507_2006_01296_x crossref_primary_10_1345_aph_1L005 crossref_primary_10_1128_AAC_01447_07 crossref_primary_10_1007_s12094_012_0861_8 crossref_primary_10_1016_j_ijantimicag_2007_03_009 crossref_primary_10_1080_14656566_2021_1996562 crossref_primary_10_1016_j_jinf_2007_06_012 crossref_primary_10_2217_17460913_2_3_231 crossref_primary_10_1016_j_clindermatol_2009_12_014 crossref_primary_10_1517_14656566_8_15_2465 crossref_primary_10_1016_j_bjid_2013_02_001 crossref_primary_10_1093_mmy_myac076 crossref_primary_10_1089_aid_2008_0254 crossref_primary_10_3109_08820139_2011_599088 crossref_primary_10_1093_cid_civ933 crossref_primary_10_1007_s11046_009_9193_9 crossref_primary_10_1016_j_jcms_2009_03_017 crossref_primary_10_1111_j_1365_2125_2010_03680_x crossref_primary_10_2217_hiv_10_18 crossref_primary_10_1086_504328 crossref_primary_10_1016_S1413_8670_12_70336_7 crossref_primary_10_2217_17460913_2_3_245 crossref_primary_10_2165_11319340_000000000_00000 crossref_primary_10_1111_j_1439_0507_2008_01571_x crossref_primary_10_3390_microbiolres13020019 crossref_primary_10_1016_j_ctro_2019_10_006 crossref_primary_10_1086_510677 crossref_primary_10_1111_odi_12103 crossref_primary_10_1016_j_ijantimicag_2025_107482 crossref_primary_10_1093_mmy_myw069 crossref_primary_10_1016_j_jchromb_2011_10_008 crossref_primary_10_1111_1469_0691_12042 crossref_primary_10_1111_1469_0691_12041 crossref_primary_10_1517_13543784_15_11_1319 crossref_primary_10_1111_j_1469_0691_2008_01981_x crossref_primary_10_1179_joc_2008_20_6_661 crossref_primary_10_4103_0022_3859_65281 crossref_primary_10_2146_ajhp070532 crossref_primary_10_1111_hiv_12806 crossref_primary_10_1111_j_1439_0507_2011_02040_x crossref_primary_10_1002_jccs_201500161 crossref_primary_10_3390_jof1030345 crossref_primary_10_1016_j_burns_2010_01_005 crossref_primary_10_1128_CMR_00046_13 crossref_primary_10_1128_JCM_01952_07 crossref_primary_10_1517_14656566_2010_493875 crossref_primary_10_1016_j_idc_2015_10_012 crossref_primary_10_1086_511039 crossref_primary_10_1093_dote_doy094 crossref_primary_10_4137_CMT_S5434 crossref_primary_10_1002_phar_1533 crossref_primary_10_1146_annurev_med_59_062906_071602 crossref_primary_10_1093_cid_cis205 crossref_primary_10_1128_JCM_02161_10 crossref_primary_10_1592_phco_28_5_614 crossref_primary_10_1586_ecp_09_14 crossref_primary_10_1080_08998280_2007_11928283 crossref_primary_10_1016_j_jclinepi_2010_11_017 crossref_primary_10_1517_13543784_16_6_899 crossref_primary_10_1517_14656561003649555 crossref_primary_10_1080_14787210_2021_1922078 crossref_primary_10_1371_journal_pone_0057672 crossref_primary_10_3390_jof7080637 crossref_primary_10_1128_AAC_02465_17 crossref_primary_10_1007_s11046_021_00579_5 crossref_primary_10_1586_14787210_4_5_875 crossref_primary_10_1016_j_jpba_2006_06_011 crossref_primary_10_1086_501465 crossref_primary_10_1310_hpj4201_57 crossref_primary_10_1086_596757 crossref_primary_10_1128_AAC_01292_20 crossref_primary_10_1586_ehm_09_46 crossref_primary_10_1111_j_1468_1293_2011_00944_8_x crossref_primary_10_1016_j_tripleo_2009_11_026 crossref_primary_10_1097_QCO_0b013e3283177967 crossref_primary_10_1111_j_1365_2710_2009_01055_x crossref_primary_10_1111_j_1469_0691_2011_03646_x crossref_primary_10_1111_j_1462_5822_2009_01412_x crossref_primary_10_1128_AAC_00130_08 crossref_primary_10_1002_cncr_23152 crossref_primary_10_1007_s12281_014_0185_y crossref_primary_10_1016_j_mib_2006_08_001 crossref_primary_10_1007_s15010_008_7357_z crossref_primary_10_1517_14656566_9_16_2801 crossref_primary_10_1111_j_1439_0507_2008_01569_x crossref_primary_10_1007_s00101_009_1655_4 crossref_primary_10_3390_pharmacy2010098 crossref_primary_10_1517_14656566_8_8_1167 crossref_primary_10_1111_j_1439_0507_2011_02061_x crossref_primary_10_1016_j_jinf_2011_05_022 crossref_primary_10_1093_jac_dkl525 crossref_primary_10_1111_odi_12394
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1086/501457
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1537-6591
ExternalDocumentID	16575739
Genre	Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- ..I .2P .GJ .I3 .ZR 08P 0R~ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAYOK ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABLJU ABNGD ABNHQ ABOCM ABPLY ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ACGFO ACGFS ACHIC ACPRK ACUFI ACUTO ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADJQC ADQBN ADRIX ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AGINJ AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN AQKUS AQVQM ASPBG ATGXG AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C1A C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DCCCD DIK DILTD DOOOF DU5 D~K E3Z EBS ECM EE~ EIF EJD EMOBN ENERS ESX F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H5~ HAR HQ3 HTVGU HVGLF HW0 HZ~ IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KAQDR KBUDW KOP KSI KSN L7B M49 MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NPM NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 VH1 W8F X7H YAYTL YKOAZ YXANX ZGI ~91 ~S- 7X8 ABPQP ACUKT ADNBA ADQXQ AEMQT AGQPQ AJBYB AJNCP ALXQX JXSIZ
ID	FETCH-LOGICAL-c452t-a41ea63fd66c59ddb9f403a6ab2d4f1ad68199f3b7669e0b6eb83d484fed911d2
IEDL.DBID	7X8
ISICitedReferencesCount	129
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000236101800020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1537-6591
IngestDate	Thu Oct 02 15:39:31 EDT 2025 Wed Feb 19 01:48:18 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	8
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c452t-a41ea63fd66c59ddb9f403a6ab2d4f1ad68199f3b7669e0b6eb83d484fed911d2
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://academic.oup.com/cid/article-pdf/42/8/1179/794802/42-8-1179.pdf
PMID	16575739
PQID	67816642
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_67816642 pubmed_primary_16575739
PublicationCentury	2000
PublicationDate	2006-Apr-15 20060415
PublicationDateYYYYMMDD	2006-04-15
PublicationDate_xml	– month: 04 year: 2006 text: 2006-Apr-15 day: 15
PublicationDecade	2000
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Clinical infectious diseases
PublicationTitleAlternate	Clin Infect Dis
PublicationYear	2006
References	16575740 - Clin Infect Dis. 2006 Apr 15;42(8):1187-8
References_xml	– reference: 16575740 - Clin Infect Dis. 2006 Apr 15;42(8):1187-8
SSID	ssj0011805
Score	2.27657
Snippet	Oropharyngeal candidiasis is the most common opportunistic infection among persons infected with human immunodeficiency virus (HIV). Use of some agents is...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	1179
SubjectTerms	Adult Aged AIDS-Related Opportunistic Infections - drug therapy Antifungal Agents - therapeutic use Candida - classification Candida - isolation & purification Candidiasis - drug therapy Candidiasis, Oral - drug therapy Double-Blind Method Ethnic Groups Female Fluconazole - therapeutic use Humans Male Microbial Sensitivity Tests Middle Aged Pharyngeal Diseases - drug therapy Pharyngeal Diseases - microbiology Probability Treatment Outcome Triazoles - pharmacology Triazoles - therapeutic use
Title	A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS
URI	https://www.ncbi.nlm.nih.gov/pubmed/16575739 https://www.proquest.com/docview/67816642
Volume	42
WOSCitedRecordID	wos000236101800020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwELVoQVUvlM-Wr3YOXC3WG9uxpUpoRUEgwQqJD-1tZcc2rETj7YatBD-jv7jjbAJcEAcuOUSKFTnPMy_znj2E7BomleGCUWEV_qAgY6bKOk-VNsxiQvCirndcn-b9vhoM9Pkc-dnuhUm2yjYm1oHaxSLVyPcwqDKJZHl__IemnlFJW20aaHwg8xkSmYTpfPCsITBVGxhxSedUCs1edBaqxbT8dVJZJ5ejL-97rSWy2JBK6M1QsEzmfLlCPp01svkq-deD2jiYnJh-ApieXPw9evQO6qYd0B75Xd7AOFYYI0vzGO88JMvGtIKQbO3NLeS4gJwRngzqEAPESRzfmslDeYO0E4q0UwZhV40qGJVQTW2q9VSQSr5wfHK91zv5dbFGro4OLw-OadOMgRZcdO-p4cwbmQUnZSG0c1YH3smMNLbreGDGSeQWOmQ2l1L7jpXeqsxxxYN3GFBdd518LGPpvxHggXeDx3GYs1wIp7MiV14LbmSHu7yzQX60cz1EsCcFw5Q-TqthO9sb5Ovscw3HszM5hiwJSHmmN998dot8npVROGVim8wHXOZ-hywUf-9H1eR7jSG89s_P_gMXQ9Vz
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+multicenter+randomized+trial+evaluating+posaconazole+versus+fluconazole+for+the+treatment+of+oropharyngeal+candidiasis+in+subjects+with+HIV%2FAIDS&rft.jtitle=Clinical+infectious+diseases&rft.au=Vazquez%2C+Jose+A&rft.au=Skiest%2C+Daniel+J&rft.au=Nieto%2C+Leopoldo&rft.au=Northland%2C+Rebeca&rft.date=2006-04-15&rft.issn=1537-6591&rft.eissn=1537-6591&rft.volume=42&rft.issue=8&rft.spage=1179&rft_id=info:doi/10.1086%2F501457&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon